Skip to main content
Optimind Pharma Corp. logo

Optimind Pharma Corp. — Investor Relations & Filings

Ticker · OMND CSE Human health and social work activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-01-29 Capital/Financing Update
Country CA Canada
Listing CSE OMND

About Optimind Pharma Corp.

https://optimindpharma.com

Optimind Pharma Corp. is a provider specializing in psychedelic therapies and alternative treatments for mental health disorders. The company focuses on addressing conditions such as Post-Traumatic Stress Disorder (PTSD), anxiety, and depression. Optimind's core offerings include Psychedelic-Enhanced Psychotherapy (PEP) and Ketamine-Assisted Treatment (KAT). The treatment modalities encompass both monotherapy and assisted therapy, frequently utilizing ketamine capsules to facilitate therapeutic outcomes. Additionally, the company provides services related to the prescription of medical cannabis, integrating these various approaches to deliver comprehensive mental wellness solutions.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Capital/Financing Update Classification · 1% confidence The document is a pricing supplement and prospectus for the issuance of a new debt security (Bank of Montreal Callable Contingent Income Barrier Notes). It details the terms of the offering, coupon, maturity, underwriting, and tax considerations. This clearly constitutes a capital-raising financing activity rather than an earnings release, management discussion, or regulatory notice. Therefore, it is classified as a Capital/Financing Update (CAP).
2025-01-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is Form 52-109FV2 “Certification of Interim Filings” by the CFO certifying the interim financial report and interim MD&A. It is not the interim report itself but a regulatory certificate required under NI 52-109. This does not match any specific category like an IR report, earnings release, or audit report; it is a regulatory filing. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2025-01-29 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled "Management Discussion and Analysis" for the three and nine months ended November 30, 2024, and provides unaudited interim financial commentary, forward-looking statements, business overview and trends. This matches the definition of a Management Reports (MD&A) filing rather than a full interim report or an earnings release.
2025-01-29 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the three and nine months ended November 30, 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. 9M 2025
2025-01-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-10-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-10-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.